|
KLRC4-KLRK1
|
Leukemia, Myelocytic, Acute
|
0.090 |
AlteredExpression |
BEFREE |
In this study, we tested NK cell activity against KG1a (AML cell line) with and without two types of pretreatment-Ara-C treatment that induced NKG2D ligands (increased activating signal) and/or blocking of HLA-KIR (killer-immunoglobulin-like receptors) interaction (decreased inhibitory signal).
|
31311121 |
2019 |
|
KLRC4-KLRK1
|
Leukemia, Myelocytic, Acute
|
0.090 |
AlteredExpression |
BEFREE |
AML cells with LSC properties can be isolated by their lack of expression of NKG2D ligands (NKG2DLs) in both CD34-expressing and non-CD34-expressing cases of AML.
|
31316209 |
2019 |
|
KLRC4-KLRK1
|
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker |
BEFREE |
Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia.
|
31142382 |
2019 |
|
KLRC4-KLRK1
|
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker |
BEFREE |
We present comprehensive data on manufacturing development and clinical production of autologous NKG2D CAR T cells for treatment of acute myeloid leukemia and multiple myeloma (ClinicalTrials.gov Identifier: NCT02203825).
|
30180944 |
2018 |
|
KLRC4-KLRK1
|
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker |
BEFREE |
Natural killer (NK) cells play an important role in the recognition of AML blasts through the interaction of the activating NKG2D receptor with its ligands (NKG2DL: MICA/B and ULBPs1-3).
|
28404876 |
2017 |
|
KLRC4-KLRK1
|
Leukemia, Myelocytic, Acute
|
0.090 |
AlteredExpression |
BEFREE |
This study provides for the first time, the c-Myc dependent regulation of NKG2D ligands in AML.
|
24677544 |
2014 |
|
KLRC4-KLRK1
|
Leukemia, Myelocytic, Acute
|
0.090 |
AlteredExpression |
BEFREE |
Herein, we show that in vivo administration of all-trans-retinoic acid (ATRA) or the histone deacetylase inhibitor sodium valproate (VPA) to patients affected with acute myeloid leukaemia (AML) M3 or M1 respectively, leads to the induction of transcription and expression of NKG2D-L at the surface of leukaemic cells.
|
19151770 |
2009 |
|
KLRC4-KLRK1
|
Leukemia, Myelocytic, Acute
|
0.090 |
AlteredExpression |
BEFREE |
Interestingly, flow cytometry analysis of 20 samples of patients with acute myeloid leukemia (AML) (FAB M0-M5) revealed the expression of NKG2D (40%) and other natural cytotoxicity receptors (40% for NKp30, 74% for NKp44, 39% for NKp46) by a pool >15% of leukemic cells.
|
16239914 |
2005 |
|
KLRC4-KLRK1
|
Leukemia, Myelocytic, Acute
|
0.090 |
AlteredExpression |
BEFREE |
We conclude that the ligand-negative/low phenotype in AML is a consequence of cell maturation arrest on malignant transformation and that defective expression of ligands for the activating NKG2D and NCR receptors may compromise leukemia recognition by NK cells.
|
15657183 |
2005 |